March 14, 2018 / 12:40 PM / 3 months ago

BRIEF-Acasti Pharma Announces First Patient Randomized In Pivotal Trilogy Phase 3 Program Of CaPre

March 14 (Reuters) - Acasti Pharma Inc:

* ACASTI PHARMA ANNOUNCES FIRST PATIENT RANDOMIZED IN PIVOTAL TRILOGY PHASE 3 PROGRAM OF CAPRE IN SEVERE HYPERTRIGLYCERIDEMIA

* ACASTI PHARMA INC - ‍CONTINUE TO EXECUTE ON OUR TIMELINE TO OBTAIN TOPLINE DATA FROM TRILOGY BY END OF 2019​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below